Bispecific antibodies (BsAbs) are redefining the landscape of therapeutic design, offering dual-target precision that conventional antibodies can’t match. These specially engineered antibodies bind to either two different antigens or two distinct sites on the same antigen. BsAbs form a powerful new class of therapy which has caused excitement among the drug development community due to…